Rebecca Raabe is an Investment Partner and Founder at SPRIG Equity, a growth equity and late-stage venture capital firm dedicated to improving patient outcomes by partnering with best-in-class teams and medical technologies.

Rebecca has worked in the medical technology industry for over 15 years as an operator, investor, and consultant. As an operator, Rebecca has held various strategy and marketing roles in both public companies (Abbott Laboratories) and private medical device companies (Ulthera (acquired by Merz) and Cayenne Medical (acquired by Zimmer)). As an investor, Rebecca worked for Abbott Ventures, where she helped manage Abbott’s equity investments as well as developed and executed new franchise strategies for the business. In 2021, Rebecca joined Ballast Capital where she evaluated multiple transactions with the Ballast team.

Prior to SPRIG Equity, Rebecca worked at SPRIG Consulting providing commercialization and strategy expertise to private and public medical technology companies across various market segments. Rebecca holds an MBA from Northwestern University’s Kellogg School of Management where she majored in health enterprise management and marketing. She also holds a BA in Biochemical Sciences from Harvard University.